Los Angeles - (NewMediaWire) - April 28, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, Inc. (“Cabaletta” or “the Company”) (NASDAQ: CABA) for violations of the federal securities laws.
Investors who purchased the Company's shares pursuant and/or traceable to the Company’s initial public offering conducted on October 24, 2019 (the “IPO”), or between October 24, 2019 and December 13, 2021, inclusive (the “Class Period”), are encouraged to contact the firm before April 29, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Cabaletta’s Phase 1 trial for DSG3-CAART produced top-line data showing it worsened some participants’ disease activity scores and resulted in a need for further medication. DSG3-CAART was not as effective as the Company touted to investors. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Cabaletta, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Schall Law Firm
Brian Schall, Esq.,
The Schall Law Firm